• Sulfo-NHS-SS-Biotin: Evidence and Boundaries

  2026-10-13

  A source-grounded overview of reversible amine labeling, what a bioRxiv study reports about glycoRNA–RNA-binding-protein surface domains, and where product claims and preprint findings do not support broader mechanistic conclusions.

• Golgi Stress and the Limits of Translational Inference

  2026-10-13

  Golgi-Tracker Green is a supplier-described BODIPY FL-labeled C5-ceramide probe for live-cell Golgi apparatus imaging. A separate 2026 study reported that the NIR dye CA800-PR induced Golgi fragmentation and antitumor effects in hormone receptor-positive breast-cancer models. The findings support Golgi stress as a research question, but they do not establish that Golgi-Tracker Green has therapeutic activity or that the two dyes are interchangeable.

• IEM-1925 in Soman Seizure Research

  2026-10-12

  A 2026 rat study examined whether dual AMPA/NMDA glutamate-receptor antagonism could reduce soman-associated status epilepticus, brain injury, and behavioral impairment. The findings support a receptor-level mechanism for further investigation, but they do not establish clinical efficacy or provide evidence that IEM 1460 was used in the study.

• BaP and Prostate Cancer: What the Evidence Shows

  2026-10-12

  A source-grounded overview of a 2025 study linking benzo[a]pyrene exposure with prostate-cancer growth and altered immune-cell infiltration, with attention to model limitations and the conceptual role of EdU-based S-phase measurement.

• RNA Synthesis Tools and Viral Immune Evasion

  2026-10-11

  A source-grounded overview distinguishes findings from a 2024 SARS-CoV-2 nucleocapsid study from supplier-described capabilities of the HyperScribe™ SP6 High Yield RNA Synthesis Kit. It explains the proposed GADD34–G3BP1–IRF3 mechanism, assesses evidence strength, and defines boundaries for interpreting RNA synthesis technologies in viral-immunity research.

• SB203580 Beyond Inhibition: Translational MAPK Strategy

  2026-10-10

  SB203580 is more than a p38 pathway blocker: it is a mechanistic probe for separating stress signaling from compensatory survival networks. This thought-leadership perspective connects the compound’s reported biochemical profile with the HDAC8–PLCB1–AKT resistance biology described in Cells, while defining evidence boundaries for translational researchers.

• Deferasirox at the Lysosome–Iron Stress Interface

  2026-10-09

  Deferasirox is best understood not only as an oral iron chelator, but also as a context-dependent probe of iron availability, oxidative signaling, and cellular stress. This article interprets the 2025 TCF25 study without overstating its relevance to cancer or lysosomal cell death.

• Fucoidan, Irinotecan, and the Gut–Liver Axis

  2026-10-08

  A 2026 study identifies intestinal barrier disruption, LPS translocation, and hepatic neutrophil extracellular traps as connected features of CPT-11-induced steatohepatitis in mice. Its findings position fucoidan as a candidate for studying gut–liver inflammatory mechanisms, while leaving clinical efficacy, tumor control, and human transferability unresolved.

• Cy5 Antibody and ASB3–MAVS Evidence Explained

  2026-10-08

  A source-grounded overview of ASB3–MAVS antiviral signaling, the strength and limits of the 2024 evidence, and how a Cy5 secondary antibody should be interpreted as a detection tool rather than proof of mechanism.

• BV6 and the Next Logic of Apoptosis Translation

  2026-10-07

  BV6 offers a mechanism-focused way to study how IAP signaling shapes apoptosis, treatment response, and disease biology. This evidence-led perspective connects reported BV6 findings with a recent ovarian cancer cachexia study, highlighting translational opportunities while separating mechanistic promise from clinical proof.

• Toremifene for Breast Cancer: 20 Years of Evidence

  2026-10-07

  This review synthesizes two decades of clinical experience with toremifene, presenting it as an evidence-supported endocrine option for selected postmenopausal patients with hormone-sensitive breast cancer. Its main contribution is an integrated comparison of efficacy, safety, pharmacokinetics, CYP2D6-related metabolism, and differences from aromatase inhibitors rather than a new experimental treatment.

• ABT-888 (Veliparib): Context Matters

  2026-10-06

  ABT-888 (Veliparib) is a selective PARP1/2 inhibitor used to investigate DNA repair inhibition and treatment sensitization. This analysis places its colorectal and MSI-model evidence alongside a recent leukemia study showing why PARP biology, TP53 status, and damage type must be interpreted together.

• SN-38 Beyond TOP1: A Translational Research Lens

  2026-10-06

  7-Ethyl-10-hydroxycamptothecin, also known as SN-38, is best understood as a mechanistically rich research tool rather than only a DNA topoisomerase I inhibitor. This thought-leadership article connects the TOP1 inhibition pathway with FUBP1–FUSE biology, evaluates the strength of the evidence, and outlines translational questions for advanced colon cancer research without overstating clinical applicability.

• PreScission Protease: Research Context and Evidence

  2026-10-05

  PreScission Protease is a recombinant HRV 3C protease used conceptually for precise fusion protein tag cleavage. This overview separates supplier-described enzyme properties from peer-reviewed findings on Drosophila Keap1 and lamin Dm0, comparing evidence strength, research applications, and limitations.

• Microplastics, Nanoplastics, and Pulmonary Fibrosis

  2026-10-05

  A 2026 Toxicology study compared polystyrene, polyethylene, and polypropylene microplastics and nanoplastics in mouse and human lung-cell models, identifying polymer- and size-dependent pulmonary toxicity. Its results implicate dysregulation of the FXR–YAP1 axis in fibrosis-associated responses, while the experimental scope remains preclinical and does not establish human disease risk.

8543 records 1/570 page Next 12345 下5页 Last page